HeartSciences Inc. (NASDAQ:HSCS) Short Interest Update

HeartSciences Inc. (NASDAQ:HSCS) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 41,615 shares, an increase of 36.3% from the January 15th total of 30,531 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average daily volume of 35,393 shares, the short-interest ratio is presently 1.2 days. Based on an average daily volume of 35,393 shares, the short-interest ratio is presently 1.2 days. Approximately 1.3% of the shares of the stock are short sold.

HeartSciences Stock Up 0.8%

NASDAQ:HSCS traded up $0.03 during trading hours on Tuesday, hitting $3.03. 3,016 shares of the stock were exchanged, compared to its average volume of 31,110. The company’s 50 day moving average is $2.99 and its two-hundred day moving average is $3.17. The company has a market capitalization of $9.61 million, a P/E ratio of -0.44 and a beta of 2.52. HeartSciences has a twelve month low of $2.01 and a twelve month high of $6.47.

HeartSciences (NASDAQ:HSCS) last posted its quarterly earnings results on Monday, December 15th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.05. The business had revenue of $2.42 million for the quarter, compared to the consensus estimate of $0.00 million. On average, equities research analysts expect that HeartSciences will post -10.01 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on HSCS shares. Ascendiant Capital Markets lifted their price objective on HeartSciences from $9.00 to $9.20 and gave the company a “buy” rating in a report on Monday, December 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, HeartSciences currently has an average rating of “Hold” and an average target price of $9.20.

Hedge Funds Weigh In On HeartSciences

Several institutional investors and hedge funds have recently made changes to their positions in HSCS. DRW Securities LLC raised its stake in HeartSciences by 13.7% during the 4th quarter. DRW Securities LLC now owns 95,065 shares of the company’s stock worth $294,000 after buying an additional 11,455 shares during the period. Geode Capital Management LLC increased its holdings in shares of HeartSciences by 110.7% in the fourth quarter. Geode Capital Management LLC now owns 26,928 shares of the company’s stock worth $83,000 after acquiring an additional 14,150 shares in the last quarter. Finally, TFB Advisors LLC bought a new position in shares of HeartSciences during the 3rd quarter valued at about $105,000. Institutional investors and hedge funds own 17.24% of the company’s stock.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.